Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. (Q52868558)

From Wikidata

Jump to navigation Jump to search

scientific article published on 19 March 2015

Language	Label	Description	Also known as
English	Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.	scientific article published on 19 March 2015

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25787915%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25787915%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25787915%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

U Bertsch

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25787915%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

J Dürig

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25787915%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

C Kunz

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25787915%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

M Haenel

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25787915%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

I W Blau

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25787915%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

M Munder

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25787915%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

A Jauch

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25787915%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

B Schurich

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25787915%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

T Hielscher

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25787915%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

M Merz

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25787915%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

B Huegle-Doerr

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25787915%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

A Seckinger

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25787915%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

D Hose

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25787915%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

J Hillengass

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25787915%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

M S Raab

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25787915%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

K Neben

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25787915%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

H-W Lindemann

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25787915%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

M Zeis

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25787915%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

C Gerecke

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25787915%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

I G H Schmidt-Wolf

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25787915%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

K Weisel

22

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25787915%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

C Scheid

23

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25787915%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

H Salwender

24

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25787915%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

H Goldschmidt

25

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25787915%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

publication date

19 March 2015

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25787915%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25787915%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

29

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25787915%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25787915%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1721-1729

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25787915%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

https://scigraph.springernature.com/pub.10.1038/leu.2015.80

0 references

Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.80

21 January 2018

European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.80

21 January 2018

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.80

21 January 2018

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.80

21 January 2018

Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.80

21 January 2018

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.80

21 January 2018

Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.80

21 January 2018

Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.80

21 January 2018

Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.80

21 January 2018

Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.80

21 January 2018

A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.80

21 January 2018

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.80

21 January 2018

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.80

21 January 2018

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.80

21 January 2018

International uniform response criteria for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.80

21 January 2018

International staging system for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.80

21 January 2018

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.80

21 January 2018

Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.80

21 January 2018

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.80

21 January 2018

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.80

21 January 2018

Importance of achieving a complete response in multiple myeloma, and the impact of novel agents

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.80

21 January 2018

The role of complete response in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.80

21 January 2018

Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.80

21 January 2018

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.80

21 January 2018

Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.80

21 January 2018

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.80

21 January 2018

Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.80

21 January 2018

Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.80

21 January 2018

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.80

21 January 2018

TNF-α-mediated JNK activation in the dorsal root ganglion neurons contributes to Bortezomib-induced peripheral neuropathy.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.80

21 January 2018

Immune-mediated neuropathies in myeloma patients treated with bortezomib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.80

21 January 2018

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.80

21 January 2018

Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.80

21 January 2018

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.80

21 January 2018

Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.80

21 January 2018

Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.80

21 January 2018

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25787915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25787915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25787915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone

1 reference

https://pubmed.ncbi.nlm.nih.gov/25787915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interval estimation for the difference between independent proportions: comparison of eleven methods

1 reference

https://pubmed.ncbi.nlm.nih.gov/25787915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25787915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p

1 reference

https://pubmed.ncbi.nlm.nih.gov/25787915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25787915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/25787915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/LEU.2015.80

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25787915%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25787915%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52868558&oldid=1531083697"